BridgeBio Pharma Inc (BBIO)
23.24
+0.20
(+0.87%)
USD |
NASDAQ |
Nov 21, 16:00
23.30
+0.06
(+0.26%)
After-Hours: 07:47
BridgeBio Pharma Enterprise Value: 5.857B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 5.857B |
| November 20, 2024 | 5.819B |
| November 19, 2024 | 5.724B |
| November 18, 2024 | 5.688B |
| November 15, 2024 | 5.947B |
| November 14, 2024 | 6.021B |
| November 13, 2024 | 6.150B |
| November 12, 2024 | 6.117B |
| November 11, 2024 | 6.401B |
| November 08, 2024 | 6.584B |
| November 07, 2024 | 6.356B |
| November 06, 2024 | 6.305B |
| November 05, 2024 | 6.288B |
| November 04, 2024 | 6.227B |
| November 01, 2024 | 6.280B |
| October 31, 2024 | 5.889B |
| October 30, 2024 | 5.961B |
| October 29, 2024 | 6.095B |
| October 28, 2024 | 6.083B |
| October 25, 2024 | 5.970B |
| October 24, 2024 | 6.032B |
| October 23, 2024 | 6.085B |
| October 22, 2024 | 6.178B |
| October 21, 2024 | 6.219B |
| October 18, 2024 | 6.382B |
| Date | Value |
|---|---|
| October 17, 2024 | 6.414B |
| October 16, 2024 | 6.442B |
| October 15, 2024 | 6.261B |
| October 14, 2024 | 6.337B |
| October 11, 2024 | 6.359B |
| October 10, 2024 | 6.182B |
| October 09, 2024 | 5.883B |
| October 08, 2024 | 6.138B |
| October 07, 2024 | 6.159B |
| October 04, 2024 | 6.233B |
| October 03, 2024 | 6.308B |
| October 02, 2024 | 6.204B |
| October 01, 2024 | 6.151B |
| September 30, 2024 | 6.276B |
| September 27, 2024 | 5.970B |
| September 26, 2024 | 5.884B |
| September 25, 2024 | 5.889B |
| September 24, 2024 | 5.955B |
| September 23, 2024 | 6.057B |
| September 20, 2024 | 6.309B |
| September 19, 2024 | 6.326B |
| September 18, 2024 | 6.162B |
| September 17, 2024 | 6.307B |
| September 16, 2024 | 6.205B |
| September 13, 2024 | 6.203B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.607B
Minimum
Mar 18 2020
10.69B
Maximum
Feb 08 2021
5.194B
Average
4.850B
Median
Sep 18 2020
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals Inc | 30.08B |
| Pfizer Inc | 199.35B |
| Vertex Pharmaceuticals Inc | 109.46B |
| PTC Therapeutics Inc | 2.580B |
| Bristol-Myers Squibb Co | 159.82B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -162.04M |
| Revenue (Quarterly) | 2.732M |
| Total Expenses (Quarterly) | 189.86M |
| EPS Diluted (Quarterly) | -0.86 |
| Gross Profit Margin (Quarterly) | 78.11% |
| Profit Margin (Quarterly) | -5.93K% |
| Earnings Yield | -10.37% |
| Normalized Earnings Yield | -14.09 |